Diamyd Medical announced earlier this week that the diabetes vaccine Diamyd® has demonstrated significant effect in a subgroup which covers about half of all type 1 diabetes patients.
STOCKHOLM, Sept. 16, 2020 /PRNewswire/ -- Diamyd Medical announced earlier this week that the diabetes vaccine Diamyd® has demonstrated significant effect in a subgroup which covers about half of all type 1 diabetes patients. In connection to this, CEO Ulf Hannelius together with the trial’s Coordinating Investigator Professor Johnny Ludvigsson and Professor Mark Atkinson will hold a webcast presentation on Thursday 17 September at 15.00 CET.
The presentation is hosted by News Agency Direkt and Direkt Studios and can be watched at
https://youtu.be/UH6sr8WIbaQ
About Diamyd Medical
Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined subgroup in a large-scale metastudy as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine is administered directly into a lymph node in children and young adults with newly diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.
Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46-8-528-00-399, e-mail: info@fnca.se.
For further information, please contact:
Ulf Hannelius
President and CEO
Phone: +46-736-35-42-41
E-mail: ulf.hannelius@diamyd.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/diamyd-medical-invites-to-a-webcast-presentation-on-september-17-on-the-results-from-diagnode-2-301132176.html
View original content:SOURCE Diamyd Medical AB
Company Codes: Frankfurt:DMN, ISIN:SE0005162880, Stockholm:DMYD-B.ST
